Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Immunohistochemical and Molecular Characteristics of Follicular Patterned Thyroid Nodules with Incomplete Nuclear Features of Papillary Thyroid Carcinoma

´ëÇѺ´¸®ÇÐȸÁö 2009³â 43±Ç 6È£ p.495 ~ 502
¹ÎÇý¼÷, °­°æÈÆ, Ãֱ⿵, Á¶³²À±, ¹Ú¼Ò¿¬, ¹Ú¼ºÈ£,
¼Ò¼Ó »ó¼¼Á¤º¸
¹ÎÇý¼÷ ( Min Hye-Sook ) 
±¹¸³¾Ï¼¾ÅÍ º´¸®°ú

°­°æÈÆ ( Kang Gyeong-Hoon ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
Ãֱ⿵ ( Choe Ghee-Young ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
Á¶³²À± ( Cho Nam-Yun ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¾Ï¿¬±¸¼Ò
¹Ú¼Ò¿¬ ( Park So-Yeon ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
¹Ú¼ºÈ£ ( Park Seong-Hoe ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


Background: Follicular patterned thyroid nodules with incomplete nuclear features of papillary thyroid carcinoma (FTN-INPTCs) are difficult to diagnose, and their biological behavior and association with follicular variants of PTC (FVPTCs) have not yet been established. The aim of this study is to determine immunohistochemical and molecular characteristics of FTN-INPTCs.

Methods: We investigated immunohistochemical features (galectin-3, HBME-1, CK19, fibronectin-1, CITED1), BRAF V600E mutation and RASSF1A promoter methylation status in 30 FTN-INPTC cases, along with 26 FVPTCs, 21 follicular adenomas (FAs) and 14 nodular hyperplasias (NHs).

Results: Expression of galectin-3, HBME-1, CK19 and CITED1 was significantly higher in FTN-INPTCs than in FAs or NHs, but expression of galectin-3, CK19 and fibronectin-1 was lower in FTN-INPTCs than in FVPTCs. The BRAF V600E mutation was not detected in the benign nodules or FTN-INPTCs, whereas 57% of FVPTCs had the mutation. RASSF1A promoter methylation was higher in FTN-INPTCs than in benign nodules but there was no difference between FTN-INPTCs and FVPTCs.

Conclusions: Our results represent the borderline immunohistochemical and molecular characteristics of FTN-INPTC. We conclude that FTN-INPTC is an intermediate lesion between a benign nodule and a FVPTC, and that it is pathogenetically related to FVPTC.

Å°¿öµå

Thyroid gland;Thyroid neoplasms;Carcinoma;Papillary

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS